Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 4
2013 1
2021 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.
Steinhardt MJ, Hegenbart U, Hellou T, Oubari S, Roussel M, Schwotzer R, Buadi F, Dingli D, Binder M, Kourelis T, Zanwar SS, Rieger MJ, Morbach C, Cejka V, Gerber B, Störk S, Einsele H, Kumar S, Gertz M, Carpinteiro A, Kortum KM, Muchtar E, Dispenzieri A, Schönland S. Steinhardt MJ, et al. Am J Hematol. 2026 Aug;101(8):1903-1914. doi: 10.1002/ajh.70371. Epub 2026 Jun 7. Am J Hematol. 2026. PMID: 42252535 Free PMC article.
We retrospectively analyzed 475 transplant-eligible patients who completed standard intensity treatment with or without HDM within 12 months at six centers in Europe and the United States between 2010 and 2024 to evaluate outcomes by baseline risk factors, hematolog …
We retrospectively analyzed 475 transplant-eligible patients who completed standard intensity treatment with or without HDM within 12 months …
A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J, Yang Y, Zhou L, Jiang M, Hou M. Zhu J, et al. BMC Cancer. 2010 May 13;10:199. doi: 10.1186/1471-2407-10-199. BMC Cancer. 2010. PMID: 20465813 Free PMC article.
Tumor response, time to progression and survival were evaluated. RESULTS: The long-term imatinib mesylate treatment was safe and well tolerated. At a median follow-up time for 39.5 months, the 3-year survival rate was 66.7%. Median TTP and OS were 37 months ( …
Tumor response, time to progression and survival were evaluated. RESULTS: The long-term imatinib mesylate treatment was safe a …
Long-term outcome of Simpson IV meningioma resection: Would it improve with adjuvant SRS?
Dedeciusova M, Majovsky M, Pecen L, Benes V, Netuka D. Dedeciusova M, et al. Clin Neurol Neurosurg. 2021 Aug;207:106766. doi: 10.1016/j.clineuro.2021.106766. Epub 2021 Jun 17. Clin Neurol Neurosurg. 2021. PMID: 34166979
Nevertheless, only a few studies have reported on patient outcome after STR. We studied the long-term outcome of SIV (Simpson grade IV) resection and identified predictive factors of overall survival (OS), progression-free survival (PFS) and time to pr …
Nevertheless, only a few studies have reported on patient outcome after STR. We studied the long-term outcome of …
Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.
Chemnitz JM, Uener J, Hallek M, Scheid C. Chemnitz JM, et al. Ann Hematol. 2010 Oct;89(10):1029-33. doi: 10.1007/s00277-010-0968-3. Epub 2010 Apr 27. Ann Hematol. 2010. PMID: 20422413
Rituximab may be used to treat patients with thrombotic thrombocytopenic purpura (TTP) refractory to plasma exchange or recurrent disease. While initial response rates are reported to be high, long-term follow-up data of patients treated with rituximab are no …
Rituximab may be used to treat patients with thrombotic thrombocytopenic purpura (TTP) refractory to plasma exchange or recurrent dis …
Outcome of multimodality treatment for 188 cases of type B3 thymoma.
Gao L, Wang C, Fang W, Zhang J, Lv C, Fu S. Gao L, et al. J Thorac Oncol. 2013 Oct;8(10):1329-34. doi: 10.1097/JTO.0b013e31829ceb50. J Thorac Oncol. 2013. PMID: 24457243 Free article.
INTRODUCTION: This study aimed to evaluate the long-term efficacy of multimodality therapy for patients with type B3 thymoma. METHODS: A total of 188 consecutive patients with type B3 were treated in our hospital from January 2001 to December 2010. ...The Mas …
INTRODUCTION: This study aimed to evaluate the long-term efficacy of multimodality therapy for patients with type B3 thymoma. …
Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome.
Yu F, Tan Y, Zhao MH. Yu F, et al. Nephrol Dial Transplant. 2010 Jan;25(1):145-52. doi: 10.1093/ndt/gfp421. Epub 2009 Aug 23. Nephrol Dial Transplant. 2010. PMID: 19703836
RESULTS: Seven patients with evidence of both TTP-HUS and renal TMA were identified in 353 patients with lupus nephritis. In comparison with 55 patients with lupus nephritis without TTP-HUS, those with TTP-HUS had a higher prevalence of acute renal failure an …
RESULTS: Seven patients with evidence of both TTP-HUS and renal TMA were identified in 353 patients with lupus nephritis. In comparis …
Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study.
Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L, Liang B, Zheng C. Yan L, et al. BMC Gastroenterol. 2021 Apr 20;21(1):182. doi: 10.1186/s12876-021-01765-x. BMC Gastroenterol. 2021. PMID: 33879085 Free PMC article.
However, there is still a lack of clinical research on whether early sequential RFA, compared with late combination therapy, can improve the long-term efficacy of initial TACE treatment. METHODS: This retrospective study investigated a cohort of patients who underwe …
However, there is still a lack of clinical research on whether early sequential RFA, compared with late combination therapy, can improve the …
External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study.
Mattiucci GC, Morganti AG, Valentini V, Ippolito E, Alfieri S, Antinori A, Crucitti A, D'Agostino GR, Di Lullo L, Luzi S, Mantini G, Smaniotto D, Doglietto GB, Cellini N. Mattiucci GC, et al. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):831-8. doi: 10.1016/j.ijrobp.2009.02.013. Epub 2009 May 8. Int J Radiat Oncol Biol Phys. 2010. PMID: 19427747 Clinical Trial.
Local control (LC), time to progression (TTP), metastases-free survival (MFS), and overall survival (OS) were analyzed by the Kaplan Meier method. ...CONCLUSIONS: Gemcitabine CT-RT seems correlated with improved outcomes. Healthier patients who are likely to complet …
Local control (LC), time to progression (TTP), metastases-free survival (MFS), and overall survival (OS) were analyzed by the Kaplan …